Company / Shareholders' Equity
Caribou Biosciences, Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$122.2M
FY2025
5-year range
-$23.4M / $387.8M
FY2021-FY2025
Trend
-66.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 5 years, ranging from -$23M in FY2021 to $388M in FY2022.
Based on SEC 10-K filings.
$122M in FY2025 with a 3-year CAGR of -32.0%.
Declined from $301M to $122M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -32.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -32.0%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 66.8% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $122.2M | -66.8% |
| FY2024 | $368.4M | +22.4% |
| FY2023 | $300.9M | -22.4% |
| FY2022 | $387.8M | +1754.8% |
| FY2021 | -$23.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026